rAAt (inhaled) Arriva/Hyland Immuno.

Article Details

Citation
Copy to clipboard

Brown WM

rAAt (inhaled) Arriva/Hyland Immuno.

Curr Opin Mol Ther. 2006 Feb;8(1):76-82.

PubMed ID
16506529 [ View in PubMed
]
Abstract

Arriva Pharmaceuticals Inc and Hyland Immuno are developing a nebulized formulation of the recombinant alpha1-antitrypsin (rAAT) for the potential treatment of respiratory disorders, including emphysema, asthma and chronic obstructive pulmonary disease. The therapy, as a nebulized formulation, is currently undergoing phase II clinical trials.

DrugBank Data that Cites this Article

Drugs